Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Finch Therapeutics Group ( (FNCH) ).
Finch Therapeutics Group has announced plans to delist its common stock from the Nasdaq and deregister it under the Securities Exchange Act, aiming to cut costs associated with SEC reporting and compliance with Nasdaq standards. The stock, previously suspended by Nasdaq, has been trading on the OTC Markets and is expected to continue there post-delisting. The company believes this move best serves its interests and those of its shareholders, although no guarantees are made about future trading on the OTC.
Find detailed analytics on FNCH stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue